We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Senator Questions FDA Sanction of Blood Substitute Trial
Senator Questions FDA Sanction of Blood Substitute Trial
March 10, 2006
Sen. Chuck Grassley (R-Iowa), chairman of the Senate Finance Committee, recently wrote a letter to FDA Acting Commissioner Andrew von Eschenbach questioning why the agency would allow a company to test a blood substitute on trauma patients in 18 states without meaningful patient consent.